Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity by Gassó Astorga, Patricia et al.
Journal of the Renin-Angiotensin-
Aldosterone System
2014, Vol. 15(4) 580 –584
© The Author(s) 2014
Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1470320313510583
jra.sagepub.com
Introduction
Hypertension is a serious public-health issue worldwide 
because of its high prevalence (it affects more than a 
quarter of the world’s adult population) and because it is 
an important risk factor in cardiovascular and kidney 
diseases.1 Hypertension is considered a complex highly 
heritable trait so that, besides potential environmental 
risks, multiple genetic factors play a role in its occur-
rence.2 Angiotensin-converting enzyme (ACE) is a key 
protein in the renin-angiotensin system that catalyses 
the conversion of angiotensin I to angiotensin II, a 
protein involved in raising systemic blood pressure. 
Consequently, ACE has become one of the most impor-
tant targets in hypertension treatment. It is well known 
that ACE inhibitors (ACEIs) produce more beneficial 
effects than a simple reduction of blood pressure, which 
explains their wide use in diverse populations; not only 
those with hypertension but also those with heart failure, 
myocardial infarction or stable coronary disease. 
However, significant heterogeneity exists with regard to 
the effectiveness and tolerability of ACEIs, which makes 
pharmacogenetic studies crucial to ensure a safer and 
more efficacious treatment for patients. ACE and other 
genes related to the renin-angiotensin system have been 
frequently considered as candidate genes in both phar-
macogenetic and cardiovascular disease risk studies.3,4 
Particularly, the insertion/deletion polymorphism in 
intron 16 of the ACE gene represents the most studied 
genetic variant, which is strongly associated with ACE 
plasma activity.5 This polymorphism has been associated 
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with a wide range of clinical outcomes including cardio-
vascular diseases, diabetic nephropathy, response to 
ACEI therapy or excess mortality in patients with type I 
diabetes.6–8 However, polymorphisms located in other 
genes indirectly related to ACE have to be taken into 
account because they can become important prediction 
markers.
In previous research performed by our group, the 
rs495828 polymorphism located in the promoter region of 
the ABO gene was found to be strongly associated with 
both risk of hypertension and ACE inhibitor-induced 
cough.9,10 While the T allele was found to be a protection 
factor for hypertension, the same allele was a risk factor 
for the cough in patients treated with ACEI. If the T allele 
gives rise to lower ACE activity, it could lead to lower risk 
of hypertension and higher bradykinin levels thus trigger-
ing the cough in patients treated with ACEI, which would 
fit with our previous results perfectly (Figure 1). There are 
very few references to this polymorphism, but it seems to 
be highly relevant as it has been associated with other fea-
tures including certain haematological traits11 and with 
venous thromboembolism.12 With the objective of testing 
the hypothesis that the T allele leads to lower ACE activity, 
which emerged from our previous studies and has been 
previously reported in Asian subjects,13 we examined 
whether there is an association between the rs495828 poly-
morphism and ACE plasma activity in a Caucasian popu-
lation. Moreover, we studied the association between ABO 
genotype and phenotype (considered as the presence of 
antigen A or absence of any antigen), and we also com-
pared the ACE plasma activity of the different ABO phe-
notype groups.
Subjects and methods
A total of 168 college students (aged between 18–31 years) 
were recruited at the School of Medicine, University of 
Barcelona. Each participant answered a questionnaire via 
an interview, which elicited demographic information 
including personal medical history. All the study partici-
pants were Caucasians. Ethnicity was determined by self-
reported ancestries. Written informed consent was obtained 
from each subject. The study was approved by the hospi-
tal’s ethics committee.
Blood samples were collected from the participating 
individuals in EDTA (K2EDTA BD Vacutainer EDTA 
tubes; Becton Dickinson, Franklin Lakes, New Jersey, 
USA) and genomic DNA was isolated using a DNA purifi-
cation kit (Puregene; Gentra Systems, Indianapolis, 
Indiana, USA). The DNA concentration was determined 
by absorbance (ND1000; NanoDrop, Wilmington, 
Delaware, USA). The rs495828 was genotyped using 
TaqMan genotyping assay (C__26744830_10; Applied 
Biosystems, Foster City, California, USA) to detect the 
genetic variant (G/T, forward strand) in chromosome posi-
tion 9: 136154867 (NCBI Build 37). A total of 11 minor 
allele homozygous subjects (TT) were found in our popu-
lation but it was only possible to engage eight of them in 
further study. We selected eight major allele homozygous 
(GG) and eight heterozygous (GT) who were age- and 
gender-matched with the minor allele homozygous sub-
jects. All 24 participants provided baseline 12-hour fasting 
blood samples. None of our volunteers were being treated 
with ACE inhibitors or any other antihypertensive treat-
ment at the time of the study. One subject declined to 
Figure 1. Schematic relationship between ABO, angiotensin-converting enzyme (ACE), risk of hypertension and ACE inhibitor-
induced cough.
582 Journal of the Renin-Angiotensin-Aldosterone System 15(4)
participate in the final analysis leaving a total of 23 partici-
pants with blood samples and genotype information.
The activity of the angiotensin-converting enzyme was 
assessed by quantifying hydrolysis of the substratum 
N-[3-(furyl)acryloyl]-L-phenylalanyglycylglycyne to 
N-[3-(furyl)acryloyl]-L-phenylalanyne and glycylglycine. 
Hydrolysis was associated with a reduction in absorption 
which was quantified at 340 nm (ACE test; LTA s.r.l, 
Milano, Italy). ABO histo-blood group was determined by 
measuring the presence or absence of antigens A and B in 
the erythrocytes, as well as the presence or absence of anti-
A and anti-B antibodies in serum or plasma. The procedure 
was performed in gel-columns (Ortho Diagnostic Systems, 
Inc., Raritan, New Jersey, USA) using the haemagglutina-
tion method.
Data were analysed using IBM SPSS statistics 20. 
Fisher’s exact test was used for categorical variables and 
the non-parametric Kruskal-Wallis or Mann-Whitney U 
tests were used for continuous variables. Fisher’s exact 
test for the 2×3 contingency table was performed using R 
statistical software. Results are expressed as mean±standard 
deviation (SD). Two samples were excluded from the anal-
ysis as the corresponding subjects had abnormal body 
mass index (BMI) values, and another was excluded due to 
a hypertensive clinical history. Statistical significance was 
set at p<0.05.
Results
In our population of 168 subjects, T allele frequency was 
22.6%, similar to that reported in European HapMap sam-
ples (18.6–21.7%). The genotype frequencies were 61.3% 
(major allele homozygous GG), 32.1% (heterozygous 
GT) and 6.5% (minor allele homozygous TT); which do 
not deviate from Hardy-Weinberg expectation. From a 
total of 11 minor allele homozygous subjects, it was only 
possible to engage eight of them in further study. Blood 
samples were collected from the eight minor allele 
homozygous and from age- and gender-matched hete-
rozygous (n=8) and major allele homozygous subjects 
(n=8) to measure ACE plasma activity and ABO histo-
blood group. Four subjects were excluded from the analy-
ses due to voluntary withdrawal, hypertensive clinical 
history or abnormal BMI. A total of six participants were 
smokers at the time of the recruitment. None of the sub-
jects were heavy alcohol users but the majority of them 
stated a sporadic alcohol use.
As shown in Table 1, there were no significant differ-
ences across ABO genotype groups with respect to gender, 
age, BMI or smoking habit. Although the highest and the 
lowest mean ACE activity values were observed in major 
and minor allele homozygous subjects, respectively, no 
significant differences were found. Similarly, lower ACE 
plasma levels were observed in T allele carriers (68.5±18.2 
U/l) compared with those subjects without the minor allele 
(80.4±19.5 U/l) but these differences also did not reach 
statistical significance. However, ABO phenotype was sig-
nificantly different across the three ABO genotype groups 
(p=0.01). Although no B histo-blood group was detected, 
subjects from the other ABO groups were present in our 
population. While only two individuals corresponded to 
the AB histo-blood group, the majority of participants cor-
responded to the A or O group (11 and 7, respectively). All 
the minor allele homozygous subjects corresponded to the 
A histo-blood group, and 12 of the 13 participants who 
expressed the A antigen (A or AB histo-blood group) were 
carriers of the minor allele T (p=0.007) (Table 1). 
Moreover, significantly lower ACE activity (64.9 ± 16.1 
U/l) was found in subjects expressing glycosyltransferase 
(A and AB histo-blood groups) compared to those not 
Table 1. Characteristics of subjects according to ABO rs495828 genotypes and ABO phenotypes.
ABO rs495828 genotypes ABO phenotypes
 Major allele 
homozygous (GG)
Heterozygous 
(GT)
Minor allele 
homozygous (TT)
p valuea Antigen A No-antigen p valuea
n 6 8 6 13 7  
Gender (male) 3/6 4/8 4/6 0.866 8/13 3/7 0.642
Age (years)b 20.8±2.5 22.6±2.9 20.8±1.9 0.215 21.6±2.9 21.4±1.9 0.810
BMI (kg/m2)b 23.5±3.6 22.6±2.8 22.9±1.5 0.332 23.0±2.2 22.9±3.5 0.526
Smokers 2/6 3/8 1/6 0.837 4/13 2/7 1.000
ACE plasma 
activity (U/l)b
80.4±19.5 70.1±20.9 66.4±15.6 0.477 64.9±16.1 85.3±17.2 0.029
ABO phenotype 
(antigen A)
1/6 6/8 6/6 0.01  
T allele ABO 
rs495828
12/13 2/7 0.007
ACE: angiotensin-converting enzyme; BMI: body mass index.
aNon-parametric Kruskal-Wallis or Mann-Whitney U test for continuous variables, Fisher’s exact test for categorical variables.
bMean±standard deviation.
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expressing the enzyme (O histo-blood group) (85.3 ± 17.2 
U/l) (p=0.029).
Discussion
After having found significant associations between the 
minor allele T of ABO rs495828 polymorphism and both 
risk of hypertension and ACE inhibitor-induced cough,9,10 
we hypothesised that these associations could be due to 
this allele giving rise to low ACE activity, as previously 
reported in an Asian population.13
To test our hypothesis, we genotyped a total of 168 
healthy subjects to classify them into the three possible 
genotype groups. For subsequent quantification of ACE 
activity, and bearing in mind the high interindividual 
variability in the activity of this enzyme, we focused on 
reducing the effect of factors other than the studied poly-
morphism. Therefore, we firstly recruited the identified 
minor allele homozygous subjects to then recruit age- 
and gender-matched heterozygous and major allele 
homozygous subjects. All of them were Caucasian and 
were not being treated with ACEIs or any other antihy-
pertensive treatment. Moreover, we ensured that BMI, 
smoking and alcohol use were similar between the three 
genotype groups.
Contrary to expectations, the results of this study do not 
support the initial hypothesis. Although a slight trend was 
detected, it was not significant. However, the minor allele 
T was strongly associated with ABO phenotype; specifi-
cally with the expression of glycosyltransferase isoform A, 
which in turn was associated with low ACE activity. The 
ABO gene encodes the glycosyltransferase that transfers 
monosaccharides to cell-surface H antigens. The three 
major isoforms A, B and O, have their own specificity and 
activity. Glycosylation of the H antigens of ABO groups A 
and B is catalysed by glycosyltransferases A (for N-acetyl 
galactosamine) and B (for D-galactose), respectively. The 
O allele does not produce an active enzyme. Differences in 
ACE glycosylation depending on ABO group would lead 
to differences in ACE activity and consequently to differ-
ences in blood pressure and hypertension risk.13–15 The 
evidence of ABO rs495828 functionality found here fur-
ther supports associations previous published between this 
polymorphism and different traits.9–12
The main limitation of this study is the small sample 
size. Taking this into account we cannot rule out that 
rs495828 may be involved, at least in part, in determin-
ing ACE activity. However, the results obtained here 
indicate that ABO phenotype would be a better predictor 
than a single polymorphism. So, it would probably be 
necessary to genotype other informative ABO variants 
associated with other histo-blood groups, such as 
rs817619 or rs8176746 (O and B histo-blood groups, 
respectively), to better predict ACE activity using ABO 
genetic markers.
Conclusion
This study clearly represents new evidence in favour of a 
relationship between ABO and ACE plasma activity. 
Although the results make the influence of the ABO rs495828 
polymorphism on ABO phenotype clear, they also show the 
ABO phenotype to be a better predictor of ACE plasma 
activity than the rs495828 ABO genotype. Pharmacogenetic 
and disease risk studies have identified many relevant genetic 
markers, but phenotypic traits cannot be ignored as they 
sometimes prove to be highly valuable. Therefore, both 
genetic and phenotypic markers should be included in future 
predictor models for earlier diagnosis of hypertension risk 
and for safer and more efficacious ACE-inhibitor treatment.
Acknowledgements
The authors wish to thank the Language Advisory Service at the 
University of Barcelona for manuscript revision.
Conflicts of interest
None declared.
Funding
This study was supported by the Catalonia Ministry of Innovation, 
Universities and Enterprise (DIUE, 2009SGR1501). PG was sup-
ported by a ‘Sara Borrell’ contract (CD09/00296) from the 
Spanish Ministry of Health, Instituto de Salud Carlos III (Fondo 
de Investigacion Sanitaria (FIS)).
References
 1. Kearney PM, Whelton M, Reynolds K, et al. Global burden 
of hypertension: Analysis of worldwide data. Lancet 2005; 
65: 217–223.
 2. Binder A. A review of the genetics of essential hyperten-
sion. Curr Opin Cardiol 2007; 22: 176–184.
 3. Jeunemaitre X. Genetics of the human renin angiotensin 
system. J Mol Med (Berl) 2008; 86: 637–641.
 4. De Denus S. Pharmacogenomic testing for angiotensin-
converting enzyme inhibitors: Getting ready for prime time. 
Pharmacogenomics 2010; 11: 1345–1348.
 5. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/dele-
tion polymorphism in the angiotensin I-converting enzyme 
gene accounting for half the variance of serum enzyme lev-
els. J Clin Invest 1990; 86: 1343–1346.
 6. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, et al. ACE pol-
ymorphisms. Circ Res 2006; 98: 1123–1133.
 7. Li X, Du Y, Du Y, et al. Correlation of angiotensin-converting 
enzyme gene polymorphism with effect of antihyperten-
sive therapy by angiotensin-converting enzyme inhibitor. J 
Cardiovasc Pharmacol Ther 2003; 8: 25–30.
 8. Færch LH, Sejling AS, Lajer M, et al. ACE genotype, pheno-
type and all-cause mortality in different cohorts of patients 
with type 1 diabetes. J Renin Angiotensin Aldosterone Syst 
2013; Published online before print July 5, 2013 DOI: 
10.1177/1470320313494431.
 9. Mas S, Gassó P, Alvarez S, et al. Pharmacogenetic predic-
tors of angiotensin-converting enzyme inhibitor-induced 
584 Journal of the Renin-Angiotensin-Aldosterone System 15(4)
cough: The role of ACE, ABO, and BDKRB2 genes. 
Pharmacogenet Genomics 2011; 21: 531–538.
 10. Gassó P, Mas S, Álvarez S, et al. A common variant of the 
ABO gene protects against hypertension in a Spanish popu-
lation. Hypertens Res 2012; 35: 592–596.
 11. Hong KW, Moon S, Kim YJ, et al. Association between the 
ABO locus and hematological traits in Korean. BMC Genet 
2012; 13: 78–84.
 12. Heit JA, Armasu SM, Asmann YW, et al. A genome-wide 
association study of venous thromboembolism identifies 
risk variants in chromosomes 1q24.2 and 9q. J Thromb 
Haemost 2012; 10: 1521–1531.
 13. Chung CM, Wang RY, Chen JW, et al. A genome-wide 
association study identifies new loci for ACE activ-
ity: Potential implications for response to ACE inhibitor. 
Pharmacogenomics J 2010; 10: 537–544.
 14. Cídl K, Strelcová L, Znojil V, et al. Angiotensin I-converting 
enzyme (ACE) polymorphism and ABO blood groups as 
factors codetermining plasma ACE activity. Exp Hematol 
1996; 24: 790–794.
 15. Vasků A, Soucek M, Hájek D, et al. Association analysis of 
24-h blood pressure records with I/D ACE gene polymor-
phism and ABO blood group system. Physiol Res 1999; 48: 
99–104.
